9/9
Positive
Late treatment study
et al., Tohoku J. Exp. Med., 2020, 252, 73-84, doi:10.1620/tjem.252.73 (Peer Reviewed)
Mortality Risk Factors among Hospitalized COVID-19 Patients in a Major Referral Center in Iran
Retrospective 459 patients in Iran 93% using HC Q, showing HC Q mortality RR 0.45, p = 0.028. HC Q was the only antiviral that showed a significant difference. Small number of control patients and subject to confounding by indication. Average admission delay 5.72 days.
death, ↓55.0%, p=0.03